BioRegenx is a company focused on regenerative health solutions and proactive healthcare that enables people to live better lives. As a holding company, BioRegenx will capture market share by acquiring intellectual property, companies, products, and services on the leading edge of regenerative health and anti-aging.
GlycoCheck BV Worldwide Patents
- United States: 8759095B2
- Canada: CA2706307C
- Europe: EP2215480B1 (Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, Norway, Poland, Portugal, Romania, Spain, Sweden, Switzerland, The Netherlands, and United Kingdom)
- China: CN101918845A
- Japan: JP5597543B2
Endocalyx Worldwide Patents
Products & Services
The products and services offered by BioRegnx subsidiaries align with the BioRegenx belief that we can live better and healthier lives through proactive healthcare and regenerative health solutions. These products include dietary supplements, medical devices, DNA health testing, PEMF therapy, and hydrogen water.
Studies Using GlycoCheck
GlycoCheck is being used by researchers in hospitals and universities in Africa, Asia, Australia, China, Europe, Japan, Russia, and the United States. More than 100 peer-reviewed published papers have been published using GlycoCheck to study the impacts of the microvascular system on topics such as:
Studies On Endocalyx
Multiple clinical studies on the effectiveness of Endocalyx Pro™ and its ingredients have been either completed or are in progress. In addition, there are many double-blind studies planned by researchers that will launch in the future. It takes years to complete these studies, and even after they are completed it can take months before the peer-reviewed research study is released to the public. Studies on conditions and diseases include: